KRAS and pancreatic intraductal papillary-mucinous neoplasm: The results presented here indicate not only that IPMN are frequently mutated for KRAS (83.3% in our series, consistent with other studies that analyze only KRAS exon 2 in IPMN [14], [15], [40]), but also that they are commonly mutated in KRAS exon 3 (41.7%).